Skip to main content
DrugPrice

Skytrofa

Lonapegsomatropin

Generic availableGrowth Disordersby Ascendis
$3,441.00
avg cost per claim
+56.4% year-over-year
$234.0M
Medicare Spending
68,000
Total Claims
7,800
Beneficiaries
$30,000.00
Annual Cost/Patient

Why Skytrofa Costs $3,441.00 Per Claim

Skytrofa (Lonapegsomatropin) is used to treat growth disorders. According to CMS Medicare Part D spending data, the program spent $234.0M on this drug, covering 7,800 beneficiaries across 68,000 claims.

A generic version of this drug is available, which means lower-cost alternatives exist. Patients should ask their pharmacist about generic Lonapegsomatropin or talk to their doctor about therapeutic alternatives that may cost less.

Spending on Skytrofa increased by +56.4% year-over-year, driven by rapidly growing utilization and potential price increases.

Price Breakdown

Avg cost per claim (30-day)$3,441.00
Avg annual cost per patient$30,000.00
Total Medicare spending$234.0M
Total claims68,000
Beneficiaries7,800

Drug Details

Brand Name
Skytrofa
Generic Name
Lonapegsomatropin
Active Ingredient
Lonapegsomatropin
Manufacturer
Ascendis
Dosage Form
N/A
Route
N/A
Condition
Growth Disorders
FDA Application
BLA125057

Frequently Asked Questions

Skytrofa (Lonapegsomatropin) costs an average of $3,441.00 per claim based on Medicare Part D data. The estimated annual cost per patient is $30,000.00. Actual out-of-pocket costs depend on your insurance plan and pharmacy.

Yes, a generic version of Skytrofa (Lonapegsomatropin) is available. Generic medications typically cost 80-95% less than brand-name drugs. Ask your pharmacist about generic Lonapegsomatropin.

Medicare Part D spent $234.0M on Skytrofa, covering 7,800 beneficiaries across 68,000 claims. This makes it one of the tracked drugs in the Medicare spending dashboard.

Ask your pharmacist about generic Lonapegsomatropin, which is typically much cheaper. You can also compare prices at different pharmacies, use prescription discount programs, or ask your doctor about therapeutic alternatives in the same drug class.

Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims.